117.75↑4.25 (3.74%)
12:00 AM,29th Sep 2023BSE : 530233
NSE :
Sector : Health care
ISIN Code : INE292C01011
Last Updated: Sep 29 2023 | 12:00 AM IST
Market Cap (₹ Cr) | 0 |
Turnover (₹ Cr) | 0.00 |
Volume (Shares) | |
Face Value | 10 |
52-WK High | 0.00 |
52-WK High Date | Invalid date |
52-WK Low | 0.00 |
52-WK Low Date | Invalid date |
All Time High | 0.00 |
All Time High Date | Invalid date |
All Time Low | 0.00 |
All Time Low Date | Invalid date |
Auro Laboratories is a manufacturer of Active Pharmaceutical Ingredients (API's) Intermediates and Generic Formulations. Auro Laboratories was founded and incorporated in 1992 at Mumbai with a manufacturing facility located at Tarapur 120 Km from Mumbai. Since inception the company has focused on providing quality pharmaceuticals while maintaining high manufacturing standards.The company's primary focus has been on Anti-Diabetic Drugs which is estimated to be one of the fastest growing therapeutic segments. Currently it manufacture Metformin Hydrochloride and Glibenclamide and are on the anvil of introducing others within this segment. Additionally it also undertake Toll/Custom Manufacturing for API's and Intermediates on contract basis. The manufacturing facility operates are per cGMP norms and has an installed capacity in excess of 500 Tonnes per annum.Auro laboratories has made its presence felt in international markets with a bulk of it production being exported to South East Asia Middle East and several European Countries. Some of the countries the company exports to are Egypt Germany Malaysia Singapore South Africa Brazil Spain and United Kingdom.The company has received ISO 9001:2000 and WHO - cGMP certifications. It has also received CERTIFICATE OF SUITABILITY (COS) from the European Directorate of Quality Medicine (EDQM) in September 2006.
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 73 |
EPS - TTM (₹) [S] | 4.92 |
P/E Ratio (X) [S] | 2.15 |
Face Value (₹) | 10 |
Latest Dividend (%) | - |
Latest Dividend Date | - |
Dividend Yield (%) | - |
Book Value Share (₹) [S] | 54.89 |
P/B Ratio (₹) [S] | 2.15 |
[*C] Consolidated [*S] Standalone |
Scheme Name ↑↓ | Amount Invested ( ₹ Cr ) ↑↓ | No Of Shares ↑↓ | Net Asset (%) ↑↓ |
---|
Date↑↓ | Broker↑↓ | Action↑↓ | Prices(Rs)↑↓ | Report |
---|---|---|---|---|
Data Not Found |
Today's Low/High | 110.00 117.75 |
Week Low/High | 108.00 118.00 |
Month Low/High | 108.00 151.00 |
Year Low/High | 52.50 151.00 |
All time Low/High | 0.70 195.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | 2.57% | % | -0.27 | -0.18% |
1 Month | -0.46% | % | 1.16 | 1.53% |
3 Month | 47.06% | % | 2.99 | 3.51% |
6 Month | 111.89% | % | 14.26 | 15.85% |
1 Year | 49.81% | % | 16.70 | 16.77% |
3 Year | 109.33% | % | 73.35 | 74.99% |
Date | Client Name | Exchange | Transaction | Quantity | Price |
---|---|---|---|---|---|
31-08-2023 | PADRONE MARKETING PVT LTD | BSE | BUY | 50000 | 134.87 |
30-06-2023 | AMIT DHANYAKUMAR CHORDIA | BSE | SELL | 31240 | 80.78 |
18-05-2023 | AMIT DHANYAKUMAR CHORDIA | BSE | BUY | 50000 | 97.64 |
10-01-2022 | VIVEK MEHROTRA | BSE | SELL | 41944 | 140.97 |
12-04-2021 | JAYSHREE VINOD SHAH | BSE | SELL | 67656 | 80.34 |
17-12-2013 | JAYSHREE VINOD SHAH | BSE | SELL | 200000 | 5.80 |
17-12-2013 | MEENA SHARAT DEORAH | BSE | BUY | 100000 | 5.80 |
17-12-2013 | SHARAT . DEORAH | BSE | BUY | 100000 | 5.80 |
22-08-2012 | SNEHALATHA SINGHI | BSE | SELL | 41322 | 6.55 |
Name | Price(In Rs) | Chg(%) | Mkt Cap(Rs Cr) | Sales(Rs Cr) | Profit(Rs Cr) | EPS(Rs) | P/E(x) |
---|
Category | Share(%) |
---|---|
Promoter | 52.09 |
Financial Institutions Banks | 0.00 |
Foreign Institutional Investors | 0.00 |
Insurance Companies | 0.00 |
Mutual Funds Uti | 0.01 |
Other Institutional Investors | 0.00 |
Indian Public | 37.58 |
Others Non Institutional Investors | 10.32 |
Custodians | 0.00 |
Announcement Date | Purpose | From | To | Remarks |
---|---|---|---|---|
Data Not Found |
Search for Price History
Date | Open | High | Low | Close | Shares | Trades |
---|---|---|---|---|---|---|
Data Not Found |
Load more
Chairman & Managing Director : Sharat Deorah
Whole-time Director : Siddhartha Deorah
Independent Director : Goverdhandas Aggarwal
Independent Director : Kailash Chandra Bubna
Independent Director : Kavita Vijayakant Sharma
Whole-time Director : Kiran Kulkarni
Company Sec. & Compli. Officer : Sweta Agarwal
Registered Office: K-56 MIDC Indl Area, Tarapur Boisar,Thane,Maharashtra-401506 Ph: 91-22-66635456
Email:auro@aurolabs.com